company background image
RNXT logo

RenovoRx NasdaqCM:RNXT Stock Report

Last Price

US$1.34

Market Cap

US$23.2m

7D

-8.8%

1Y

-60.2%

Updated

28 Mar, 2024

Data

Company Financials +

RNXT Stock Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.

RNXT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RenovoRx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RenovoRx
Historical stock prices
Current Share PriceUS$1.34
52 Week HighUS$4.60
52 Week LowUS$0.53
Beta1.12
1 Month Change2.29%
3 Month Change-41.48%
1 Year Change-60.24%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.54%

Recent News & Updates

Recent updates

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Mar 31
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Dec 16
Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

RenovoRx reports Q2 results

Aug 15

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Aug 04
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

RenovoRx names new finance CFO

Jul 19

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

Mar 16
RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

Nov 30
We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

Shareholder Returns

RNXTUS BiotechsUS Market
7D-8.8%0.9%0.4%
1Y-60.2%10.3%28.8%

Return vs Industry: RNXT underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: RNXT underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is RNXT's price volatile compared to industry and market?
RNXT volatility
RNXT Average Weekly Movement22.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: RNXT's share price has been volatile over the past 3 months.

Volatility Over Time: RNXT's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200910Shaun Bagaihttps://renovorx.com

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.

RenovoRx, Inc. Fundamentals Summary

How do RenovoRx's earnings and revenue compare to its market cap?
RNXT fundamental statistics
Market capUS$23.22m
Earnings (TTM)-US$9.16m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNXT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$9.16m
Earnings-US$9.16m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RNXT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.